Objective To explore the risk factors for hemorrhagic cystitis (HC) in children with β-thalassemia major (TM) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods A retrospective analysis was conducted on clinical data of 247 children with TM who underwent allo-HSCT at Shenzhen Children's Hospital from January 2021 to November 2022. The children were divided into an HC group (91 cases) and a non-HC group (156 cases) based on whether HC occurred after operation. Multivariable logistic regression analysis was used to explore the risk factors for HC, and the receiver operating characteristic curve was used to analyze the predictive efficacy of related factors for HC. Results Among the 247 TM patients who underwent allo-HSCT, the incidence of HC was 36.8% (91/247). Univariate analysis showed age, incompatible blood types between donors and recipients, occurrence of acute graft-versus-host disease (aGVHD), positive urine BK virus deoxyribonucleic acid (BKV-DNA), and ≥2 viral infections were associated with the development of HC after allo-HSCT (P<0.05). Multivariable analysis revealed that incompatible blood types between donors and recipients (OR=3.171, 95%CI: 1.538-6.539), occurrence of aGVHD (OR=2.581, 95%CI: 1.125-5.918), and positive urine BKV-DNA (OR=21.878, 95%CI: 9.633-49.687) were independent risk factors for HC in children with TM who underwent allo-HSCT. The receiver operating characteristic curve analysis showed that positive urine BKV-DNA alone or in combination with two other risk factors (occurrence of aGVHD, incompatible blood types between donors and recipients) had a certain accuracy in predicting the development of HC after allo-HSCT (area under the curve >0.8, P<0.05). Conclusions Incompatible blood types between donors and recipients, occurrence of aGVHD, and positive urine BKV-DNA are risk factors for HC after allo-HSCT in children with TM. Regular monitoring of urine BKV-DNA has a positive significance for early diagnosis and treatment of HC.
Key words
β-thalassemia major /
Allogeneic hematopoietic stem cell transplantation /
Hemorrhagic cystitis /
Risk factor /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 孙春红, 王晓宁, 罗敏娜, 等. 异基因造血干细胞移植后并发出血性膀胱炎的危险因素分析[J]. 中国实验血液学杂志, 2021, 29(2): 610-614. PMID: 33812439. DOI: 10.19746/j.cnki.issn1009-2137.2021.02.048.
2 潘小容, 莫霖, 黄先巧, 等. 造血干细胞移植并发出血性膀胱炎危险因素的Meta分析[J]. 护理学杂志, 2018, 33(19): 89-94. DOI: 10.3870/j.issn.1001-4152.2018.19.089.
3 广东省地中海贫血防治协会, 《中国实用儿科杂志》编辑委员会. 造血干细胞移植治疗重型β地中海贫血儿科专家共识[J]. 中国实用儿科杂志, 2018, 33(12): 935-939. DOI: 10.19538/j.ek2018120602.
4 何云燕. 造血干细胞移植后出血性膀胱炎的诊疗[J]. 临床儿科杂志, 2022, 40(1): 8-13. DOI: 10.12372/jcp.2022.21e1628.
5 康栋梁, 谭永红, 陈亚玫, 等. 不同年龄段地中海贫血患儿接受异基因造血干细胞移植后疗效的比较[J]. 中国实验血液学杂志, 2022, 30(2): 539-542. PMID: 35395993. DOI: 10.19746/j.cnki.issn1009-2137.2022.02.036.
6 熊艺颖, 蔡铎, 陈建斌, 等. 227例异基因造血干细胞移植后迟发性出血性膀胱炎危险因素分析[J]. 第三军医大学学报, 2021, 43(21): 2321-2330. DOI: 10.16016/j.1000-5404.202108044.
7 Jiang H, Geng L, Wan X, et al. Incidence and risk factors of late-onset hemorrhagic cystitis after single umbilical cord blood transplantation with myeloablative conditioning regimen[J]. Int J Hematol, 2021, 114(3): 381-389. PMID: 34117990. DOI: 10.1007/s12185-021-03168-w.
8 李莹, 杨隽, 许晓倩, 等. 异基因造血干细胞移植后出血性膀胱炎发生危险因素分析[J]. 内科理论与实践, 2020, 15(5): 326-331. DOI: 10.16138/j.1673-6087.2020.05.009.
9 徐宏贵, 方建培, 黄绍良, 等. 儿童造血干细胞移植并发出血性膀胱炎的危险因素分析与防治研究[J]. 中华儿科杂志, 2006, 44(2): 126-130. PMID: 16624030. DOI: 10.3760/j.issn:0578-1310.2006.02.014.
10 李祎. 异基因造血干细胞移植后严重的出血性膀胱炎危险因素分析及护理对策[J]. 临床护理杂志, 2020, 19(1): 52-55. DOI: 10.3969/j.issn.1671-8933.2020.01.018.
11 叶璐, 杨德彬, 李曼. 异基因造血干细胞移植术治疗儿童白血病的效果观察及复发影响因素分析[J]. 实用癌症杂志, 2023, 38(1): 59-61. DOI: 10.3969/j.issn.1001-5930.2023.01.016.
12 Mousavi SA, Moazed V, Mohebbi N, et al. Conjugated estrogen in late-onset hemorrhagic cystitis associated with hematopoietic stem cell transplantation[J]. Int J Hematol Oncol Stem Cell Res, 2017, 11(1): 13-18. PMID: 28286609. PMCID: PMC5338276.
13 黄楚雯, 屈钰华, 聂述山, 等. 儿童重型β地中海贫血造血干细胞移植后CMV感染预后分析[J]. 中国小儿血液与肿瘤杂志, 2022, 27(5): 299-304. DOI: 10.3969/j.issn.1673-5323.2022.05.003.
14 王朴英, 赵翔宇, 成娟, 等. 异基因造血干细胞移植后巨细胞病毒感染预防治疗的进展[J]. 中国感染与化疗杂志, 2022, 22(4): 515-520. DOI: 10.16718/j.1009-7708.2022.04.025.
15 李锐, 赵林娣, 蒋敏, 等. 异基因造血干细胞移植后CMV感染基因分型及其影响因素[J]. 中华医院感染学杂志, 2022, 32(16): 2467-2470. DOI: 10.11816/cn.ni.2022-220078.
16 杨蕊雪, 陈刚, 玛丽娅·木哈什, 等. 异基因造血干细胞移植后出血性膀胱炎及BK、JC病毒感染[J]. 中国社区医师, 2021, 37(2): 72-73. DOI: 10.3969/j.issn.1007-614x.2021.02.035.
17 郭敏, 吴涛, 白海, 等. 血液病患者异基因造血干细胞移植相关感染的临床特征及预后[J]. 中华血液学杂志, 2019, 40(1): 69-72. PMID: 30704232. PMCID: PMC7351692. DOI: 10.3760/cma.j.issn.0253-2727.2019.01.013.
18 Atilla E, Ate? C, Uslu A, et al. Prospective analysis of hemorrhagic cystitis and BK viremia in allogeneic hematopoietic stem cell transplantation[J]. Turk J Haematol, 2020, 37(3): 186-192. PMID: 31852035. PMCID: PMC7463211. DOI: 10.4274/tjh.galenos.2019.2019.0296.
19 Bielorai B, Shulman LM, Rechavi G, et al. CMV reactivation induced BK virus-associated late onset hemorrhagic cystitis after peripheral blood stem cell transplantation[J]. Bone Marrow Transplant, 2001, 28(6): 613-614. PMID: 11607776. DOI: 10.1038/sj.bmt.1703187.
20 任瑞瑞, 马梁明, 王涛, 等. 单倍体与同胞相合异基因造血干细胞移植治疗恶性血液病疗效观察[J]. 临床血液学杂志, 2023, 36(1): 44-48. DOI: 10.13201/j.issn.1004-2806.2023.01.009.
21 王显丁, 徐子林, 吕远航, 等. 人肝、肾ABO血型抗原表达差异的初步研究[J]. 中华移植杂志(电子版), 2020, 14(3): 177-181. DOI: 10.3877/cma.j.issn.1674-3903.2020.03.010.
PDF(672 KB)
